NCT02055157 - A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 13, 2014

Primary Completion Date

October 2, 2017

Study Completion Date

October 2, 2017

Conditions

Achondroplasia

Interventions

DRUG

BMN 111

BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.

Trial Locations (9)

Murdoch Children's Research Institute, Parkville

Johns Hopkins McKusick - Institute of Genetic Medicine, Baltimore

Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago

Institut Necker, Paris

Baylor College of Medicine, Houston

Harbor - UCLA Medical Center, Torrance

Children's Hospital & Research Center Oakland, Oakland

Vanderbilt University, Nashville

Guys & St. Thomas NHS Foundation Trust Evelina Hospital, London